{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T14:19:03Z","timestamp":1790864343939,"version":"4.1.0"},"reference-count":122,"publisher":"Bioscientifica","issue":"8","content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Neuroendocrine neoplasms (NENs) are a heterogeneous group of tumors, ranging from well-differentiated, slow-growing neuroendocrine tumor (NET) with long-term survival, to aggressive high-grade neuroendocrine carcinoma (NEC). Advances in treatment and earlier diagnosis have led to improved survival outcomes; however, data regarding patients\u2019 quality of life (QoL) during therapy and in the post-treatment phase remain limited. This narrative review aims to analyze available data on QoL in NEN patients undergoing medical therapies, including nutritional considerations, to improve and personalize therapeutic strategies. A literature search was performed using online databases, including MEDLINE (via PubMed) and Scopus, employing multiple keyword combinations up to October 2024. Somatostatin analogs (SSAs) and radioligand therapy (RLT) have demonstrated good tolerability profiles and efficacy on QoL, especially in patients with carcinoid syndrome, impacting on both physical and emotional domains. In contrast, multikinase inhibitors have been associated with declines in general health status, and sexual and physical function. Data on chemotherapy are conflicting, with some evidence suggesting a favorable QoL profile due to tumor control. Interestingly, approximately 30% of NEN survivors report persistence of symptoms related to depression. Both treatment-related side effects and disease-related symptoms may impact QoL, affecting nutritional status, which should be carefully considered. Despite standardized QoL, assessments are lacking in nutritional studies, and adherence to a Mediterranean diet seems to positively influence symptom burden in NEN patients. In conclusion, evidence supports that SSA and RLT contribute to improved QoL, likely due to symptom control. Further research is needed to better characterize the QoL impact of other therapies using standardized assessment tools, in order to optimize therapeutic management.<\/jats:p>","DOI":"10.1530\/erc-24-0303","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T15:41:49Z","timestamp":1752594109000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-8","source":"Crossref","is-referenced-by-count":7,"title":["Impact of treatment on quality of life in neuroendocrine neoplasm survivors"],"prefix":"10.1530","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3768-5803","authenticated-orcid":true,"given":"Roberta","family":"Modica","sequence":"first","affiliation":[{"name":"Endocrinology, Diabetology and Andrology Unit, Department of Clinical Medicine and Surgery, Federico II University of Naples 1 , ,","place":["Naples, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elio","family":"Benevento","sequence":"additional","affiliation":[{"name":"Endocrinology, Diabetology and Andrology Unit, Department of Clinical Medicine and Surgery, Federico II University of Naples 1 , ,","place":["Naples, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"La Salvia","sequence":"additional","affiliation":[{"name":"National Center for Drug Research and Evaluation, National Institute of Health (ISS) 2 , ,","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossella","family":"Mazzilli","sequence":"additional","affiliation":[{"name":"Endocrinology Unit, Department of Clinical and Molecular Medicine, Sant\u2019Andrea Hospital, ENETS Center of Excellence, Sapienza University of Rome 3 , ,","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Pandozzi","sequence":"additional","affiliation":[{"name":"Department of Experimental Medicine, Sapienza University of Rome 4 , ,","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Pecora","sequence":"additional","affiliation":[{"name":"Endocrinology Unit, Department of Clinical and Molecular Medicine, Sant\u2019Andrea Hospital, ENETS Center of Excellence, Sapienza University of Rome 3 , ,","place":["Rome, Italy"]},{"name":"Department of Experimental Medicine, Sapienza University of Rome 4 , ,","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Barrea","sequence":"additional","affiliation":[{"name":"Dipartimento di Benessere, Nutrizione e Sport, Universit\u00e0 Telematica Pegaso, Centro Direzionale 5 , ,","place":["Naples, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annamaria","family":"Colao","sequence":"additional","affiliation":[{"name":"Endocrinology, Diabetology and Andrology Unit, Department of Clinical Medicine and Surgery, Federico II University of Naples 1 , ,","place":["Naples, Italy"]},{"name":"National Center for Drug Research and Evaluation, National Institute of Health (ISS) 2 , ,","place":["Rome, Italy"]},{"name":"Endocrinology Unit, Department of Clinical and Molecular Medicine, Sant\u2019Andrea Hospital, ENETS Center of Excellence, Sapienza University of Rome 3 , ,","place":["Rome, Italy"]},{"name":"Department of Experimental Medicine, Sapienza University of Rome 4 , ,","place":["Rome, Italy"]},{"name":"Dipartimento di Benessere, Nutrizione e Sport, Universit\u00e0 Telematica Pegaso, Centro Direzionale 5 , ,","place":["Naples, Italy"]},{"name":"UNESCO Chair \u201cEducation for Health and Sustainable Development\u201d, Federico II University 6 , ,","place":["Naples, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antongiulio","family":"Faggiano","sequence":"additional","affiliation":[{"name":"Endocrinology Unit, Department of Clinical and Molecular Medicine, Sant\u2019Andrea Hospital, ENETS Center of Excellence, Sapienza University of Rome 3 , ,","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of NIKE Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","published-online":{"date-parts":[[2025,7,15]]},"reference":[{"key":"2026070905433222900_bib1","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1177\/1457496916645962","article-title":"Health-related quality of life, cachexia and overall survival after major upper abdominal surgery: a prospective cohort study","volume":"106","author":"Aahlin","year":"2017","journal-title":"Scand J Surg"},{"key":"2026070905433222900_bib2","doi-asserted-by":"crossref","DOI":"10.1186\/s13019-023-02435-7","article-title":"Maintaining quality of life after major lung resection for carcinoid tumor","volume":"18","author":"Abdel Jalil","year":"2023","journal-title":"J Cardiothorac Surg"},{"key":"2026070905433222900_bib3","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s11154-020-09581-6","article-title":"PRRT: identikit of the perfect patient","volume":"22","author":"Albertelli","year":"2021","journal-title":"Rev Endocr Metab Disord"},{"key":"2026070905433222900_bib4","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.2967\/jnumed.121.263056","article-title":"Safety of peptide receptor radionuclide therapy with 177Lu-DOTATATE in neuroendocrine tumor patients with chronic kidney disease","volume":"63","author":"Alsadik","year":"2022","journal-title":"J Nucl Med"},{"key":"2026070905433222900_bib5","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S1542-3565(05)00481-7","article-title":"Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial","volume":"3","author":"Arnold","year":"2005","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026070905433222900_bib6","doi-asserted-by":"crossref","first-page":"3507","DOI":"10.2147\/CMAR.S372776","article-title":"Capecitabine and temozolomide (CAPTEM) in advanced neuroendocrine neoplasms (NENs): a systematic review and pooled analysis","volume":"14","author":"Arrivi","year":"2022","journal-title":"Cancer Manag Res"},{"key":"2026070905433222900_bib7","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1002\/cncr.22272","article-title":"Lanreotide autogel every 6 weeks compared with lanreotide microparticles every 3 weeks in patients with well differentiated neuroendocrine tumors: a phase III study","volume":"107","author":"Bajetta","year":"2006","journal-title":"Cancer"},{"key":"2026070905433222900_bib8","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1007\/s00259-019-04567-2","article-title":"Broadening horizons with 225Ac-DOTATATE targeted alpha therapy for gastroenteropancreatic neuroendocrine tumour patients stable or refractory to 177Lu-DOTATATE PRRT: first clinical experience on the efficacy and safety","volume":"47","author":"Ballal","year":"2020","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"2026070905433222900_bib9","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.3390\/nu10121854","article-title":"Impact of nutritional status on gastroenteropancreatic neuroendocrine tumors (GEP-NET) aggressiveness","volume":"10","author":"Barrea","year":"2018","journal-title":"Nutrients"},{"key":"2026070905433222900_bib10","doi-asserted-by":"crossref","DOI":"10.1530\/ERC-23-0337","article-title":"Treatment of advanced BP-NETS with lanreotide autogel\/depot vs placebo: the phase III SPINET study","volume":"31","author":"Baudin","year":"2024","journal-title":"Endocr Relat Cancer"},{"key":"2026070905433222900_bib11","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1097\/MPA.0b013e3182328045","article-title":"Comparison of health-related quality of life in patients with neuroendocrine tumors with quality of life in the general US population","volume":"41","author":"Beaumont","year":"2012","journal-title":"Pancreas"},{"key":"2026070905433222900_bib12","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1007\/s00268-022-06479-z","article-title":"Anxiety, depression and quality of life in patients with neuroendocrine neoplasia after surgery","volume":"46","author":"Begum","year":"2022","journal-title":"World J Surg"},{"key":"2026070905433222900_bib13","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1634\/theoncologist.2012-0044","article-title":"FDA approval summary: sunitinib for the treatment of progressive well-differentiated locally advanced or metastatic pancreatic neuroendocrine tumors","volume":"17","author":"Blumenthal","year":"2012","journal-title":"Oncologist"},{"key":"2026070905433222900_bib14","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1007\/s00259-011-1902-1","article-title":"Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I\u2013II study","volume":"38","author":"Bodei","year":"2011","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"2026070905433222900_bib15","doi-asserted-by":"crossref","first-page":"e034393","DOI":"10.1136\/bmjopen-2019-034393","article-title":"Randomised phase II trial of CAPTEM or FOLFIRI as SEcond-line therapy in NEuroendocrine CArcinomas and exploratory analysis of predictive role of PET\/CT imaging and biological markers (SENECA trial): a study protocol","volume":"10","author":"Bongiovanni","year":"2020","journal-title":"BMJ Open"},{"key":"2026070905433222900_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0895-4356(99)00123-7","article-title":"Validation of the United States\u2019 version of the World Health Organization Quality of Life (WHOQOL) instrument","volume":"53","author":"Bonomi","year":"2000","journal-title":"J Clin Epidemiol"},{"key":"2026070905433222900_bib17","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/1477-7525-1-60","article-title":"The Quality of Life Scale (QOLS): reliability, validity, and utilization","volume":"1","author":"Burckhardt","year":"2003","journal-title":"Health Qual Life Outcome"},{"key":"2026070905433222900_bib18","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1056\/NEJMoa1316158","article-title":"Lanreotide in metastatic enteropancreatic neuroendocrine tumors","volume":"371","author":"Caplin","year":"2014","journal-title":"N Engl J Med"},{"key":"2026070905433222900_bib19","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1200\/JCO.1993.11.3.570","article-title":"The functional assessment of cancer therapy scale: development and validation of the general measure","volume":"11","author":"Cella","year":"1993","journal-title":"J Clin Oncol"},{"key":"2026070905433222900_bib20","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1016\/j.clinthera.2018.10.008","article-title":"Relationship between symptoms and health-related quality-of-life benefits in patients with Carcinoid syndrome: post hoc analyses from TELESTAR","volume":"40","author":"Cella","year":"2018","journal-title":"Clin Ther"},{"key":"2026070905433222900_bib22","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.ecl.2018.04.006","article-title":"Current chemotherapy use in neuroendocrine tumors","volume":"47","author":"Chan","year":"2018","journal-title":"Endocrinol Metab Clin N Am"},{"key":"2026070905433222900_bib21","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa2403991","article-title":"Phase 3 trial of cabozantinib to treat advanced neuroendocrine tumors","volume":"392","author":"Chan","year":"2024","journal-title":"N Engl J Med"},{"key":"2026070905433222900_bib23","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1159\/000500135","article-title":"Activity and safety of standard and prolonged capecitabine\/temozolomide administration in patients with advanced neuroendocrine neoplasms","volume":"109","author":"Chatzellis","year":"2019","journal-title":"Neuroendocrinology"},{"key":"2026070905433222900_bib24","doi-asserted-by":"crossref","first-page":"3582","DOI":"10.1007\/s00259-021-05332-0","article-title":"177Lu-DOTATATE in older patients with metastatic neuroendocrine tumours: safety, efficacy and health-related quality of life","volume":"48","author":"Chen","year":"2021","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"2026070905433222900_bib25","doi-asserted-by":"crossref","DOI":"10.1007\/s11912-021-01029-7","article-title":"Epidemiology, incidence, and prevalence of neuroendocrine neoplasms: are there global differences?","volume":"23","author":"Das","year":"2021","journal-title":"Curr Oncol Rep"},{"key":"2026070905433222900_bib26","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","article-title":"Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States","volume":"3","author":"Dasari","year":"2017","journal-title":"JAMA Oncol"},{"key":"2026070905433222900_bib27","doi-asserted-by":"crossref","first-page":"L23","DOI":"10.1530\/ERC-17-0549","article-title":"Towards optimal personalized diet and vitamin supplementation in NET patients","volume":"25","author":"De Hosson","year":"2018","journal-title":"Endocr Relat Cancer"},{"key":"2026070905433222900_bib28","doi-asserted-by":"crossref","first-page":"307","DOI":"10.2165\/11207360-000000000-00000","article-title":"Sunitinib: in advanced, well differentiated pancreatic neuroendocrine tumors","volume":"25","author":"Deeks","year":"2011","journal-title":"BioDrugs"},{"key":"2026070905433222900_bib29","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1007\/s00259-018-4209-7","article-title":"Personalized 177 Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: initial results from the P-PRRT trial","volume":"46","author":"Del Prete","year":"2019","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"2026070905433222900_bib30","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-022-10443-4","article-title":"A prospective, randomized, phase II study to assess the schemas of retreatment with lutathera\u00ae in patients with new progression of an intestinal, well-differentiated neuroendocrine tumor (ReLUTH)","volume":"22","author":"Deshayes","year":"2022","journal-title":"BMC Cancer"},{"key":"2026070905433222900_bib31","doi-asserted-by":"crossref","first-page":"3098","DOI":"10.1016\/j.ejca.2014.10.002","article-title":"Bevacizumab combined with 5-FU\/streptozocin in patients with progressive metastatic well-differentiated pancreatic endocrine tumours (BETTER trial) \u2013 a phase II non-randomised trial","volume":"50","author":"Ducreux","year":"2014","journal-title":"Eur J Cancer"},{"key":"2026070905433222900_bib32","doi-asserted-by":"crossref","DOI":"10.1111\/jne.13342","article-title":"Improved health-related quality of life during peptide receptor radionuclide therapy in patients with neuroendocrine tumours","volume":"35","author":"Edfeldt","year":"2023","journal-title":"J Neuroendocrinol"},{"key":"2026070905433222900_bib33","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s11154-021-09638-0","article-title":"Chemotherapy in NEN: still has a role?","volume":"22","author":"Espinosa-Olarte","year":"2021","journal-title":"Rev Endocr Metab Disord"},{"key":"2026070905433222900_bib34","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1080\/14740338.2017.1354984","article-title":"The safety of available treatments options for neuroendocrine tumors","volume":"16","author":"Faggiano","year":"2017","journal-title":"Expet Opin Drug Saf"},{"key":"2026070905433222900_bib35","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s11154-020-09547-8","article-title":"Serotonin pathway in carcinoid syndrome: clinical, diagnostic, prognostic and therapeutic implications","volume":"21","author":"Fanciulli","year":"2020","journal-title":"Rev Endocr Metab Disord"},{"key":"2026070905433222900_bib36","doi-asserted-by":"crossref","first-page":"7557","DOI":"10.3390\/jcm12247557","article-title":"Predictive factors of response to streptozotocin in neuroendocrine pancreatic neoplasms","volume":"12","author":"Fanciulli","year":"2023","journal-title":"J Clin Med"},{"key":"2026070905433222900_bib37","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1210\/clinem\/dgae707","article-title":"Octreotide subcutaneous depot for acromegaly: a randomized, double-blind, placebo-controlled phase 3 trial, ACROINNOVA 1","volume":"110","author":"Ferone","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070905433222900_bib38","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1111\/j.1365-2036.2010.04479.x","article-title":"Deficiencies in fat-soluble vitamins in long-term users of somatostatin analogue","volume":"32","author":"Fiebrich","year":"2010","journal-title":"Aliment Pharmacol Therapeut"},{"key":"2026070905433222900_bib39","doi-asserted-by":"crossref","first-page":"5106","DOI":"10.1200\/JCO.2007.12.2341","article-title":"Standardizing patient-reported outcomes assessment in cancer clinical trials: a patient-reported outcomes measurement information system initiative","volume":"25","author":"Garcia","year":"2007","journal-title":"J Clin Oncol"},{"key":"2026070905433222900_bib40","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/01.PPO.0000434391.11187.c3","article-title":"Symptoms and symptom management in long-term cancer survivors","volume":"19","author":"Gosain","year":"2013","journal-title":"Cancer J"},{"key":"2026070905433222900_bib41","article-title":"The unmet information needs, quality of life, and care experiences of patients with neuroendocrine tumours (NETs) at follow-up: 6 months from diagnosis","volume":"31","author":"Guccione","year":"2023","journal-title":"Support Care Cancer"},{"key":"2026070905433222900_bib42","doi-asserted-by":"crossref","first-page":"e13390","DOI":"10.1097\/MD.0000000000013390","article-title":"Impact of carcinoid syndrome symptoms and long-term use of somatostatin analogs on quality of life in patients with carcinoid syndrome: a survey study","volume":"97","author":"Halperin","year":"2018","journal-title":"Medicine"},{"key":"2026070905433222900_bib43","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-019-5459-x","article-title":"Assessment of change in quality of life, carcinoid syndrome symptoms and healthcare resource utilization in patients with carcinoid syndrome","volume":"19","author":"Halperin","year":"2019","journal-title":"BMC Cancer"},{"key":"2026070905433222900_bib44","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s11136-009-9487-x","article-title":"Health related quality of life in patients with neuroendocrine tumors compared with the general Norwegian population","volume":"18","author":"Haugland","year":"2009","journal-title":"Qual Life Res"},{"key":"2026070905433222900_bib45","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1093\/jjco\/hyab076","article-title":"Current status of medical treatment for gastroenteropancreatic neuroendocrine neoplasms and future perspectives","volume":"51","author":"Hijioka","year":"2021","journal-title":"Jpn J Clin Oncol"},{"key":"2026070905433222900_bib46","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1002\/pon.1137","article-title":"The development and evaluation of a measure to assess cancer survivors\u2019 unmet supportive care needs: the CaSUN (Cancer Survivors\u2019 Unmet Needs measure)","volume":"16","author":"Hodgkinson","year":"2007","journal-title":"Psychooncology"},{"key":"2026070905433222900_bib47","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1159\/000516958","article-title":"Long-term treatment with telotristat ethyl in patients with carcinoid syndrome symptoms: results from the TELEPATH study","volume":"112","author":"H\u00f6rsch","year":"2022","journal-title":"Neuroendocrinology"},{"key":"2026070905433222900_bib48","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s10637-017-0466-8","article-title":"Phase II study of lanreotide autogel in Japanese patients with unresectable or metastatic well-differentiated neuroendocrine tumors","volume":"35","author":"Ito","year":"2017","journal-title":"Invest New Drugs"},{"key":"2026070905433222900_bib49","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1158\/1055-9965.EPI-11-0563","article-title":"Consideration of quality of life in cancer survivorship research","volume":"20","author":"Jacobsen","year":"2011","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2026070905433222900_bib50","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/j.hpb.2022.02.013","article-title":"Quality of life after pancreatic surgery \u2013 a systematic review","volume":"24","author":"James","year":"2022","journal-title":"HPB"},{"key":"2026070905433222900_bib51","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/S1470-2045(08)70128-1","article-title":"Improvement of informed consent and the quality of consent documents","volume":"9","author":"Jefford","year":"2008","journal-title":"Lancet Oncol"},{"key":"2026070905433222900_bib52","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1055\/s-0042-1755412","article-title":"Peptide receptor radionuclide therapy using 177 Lu-DOTATATE in advanced neuroendocrine tumors (NETs) in a limited-resource environment","volume":"21","author":"Kalantarhormozi","year":"2022","journal-title":"World J Nucl Med"},{"key":"2026070905433222900_bib53","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.2967\/jnumed.111.087932","article-title":"Quality of life in 265 patients with gastroenteropancreatic or bronchial neuroendocrine tumors treated with [ 177Lu-DOTA 0,Tyr 3]octreotate","volume":"52","author":"Khan","year":"2011","journal-title":"J Nucl Med"},{"key":"2026070905433222900_bib54","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1002\/cncr.31192","article-title":"Phase 1b study of pasireotide, everolimus, and selective internal radioembolization therapy for unresectable neuroendocrine tumors with hepatic metastases","volume":"124","author":"Kim","year":"2018","journal-title":"Cancer"},{"key":"2026070905433222900_bib55","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1159\/000162876","article-title":"Chromogranin A as an alternative to 5-hydroxyindoleacetic acid in the evaluation of symptoms during treatment of patients with neuroendocrine tumors","volume":"89","author":"Korse","year":"2009","journal-title":"Neuroendocrinology"},{"key":"2026070905433222900_bib56","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1530\/ERC-14-0173","article-title":"Telotristat etiprate, a novel serotonin synthesis inhibitor, in patients with carcinoid syndrome and diarrhea not adequately controlled by octreotide","volume":"21","author":"Kulke","year":"2014","journal-title":"Endocr Relat Cancer"},{"key":"2026070905433222900_bib57","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1200\/JCO.2016.69.2780","article-title":"Telotristat ethyl, a tryptophan hydroxylase inhibitor for the treatment of carcinoid syndrome","volume":"35","author":"Kulke","year":"2017","journal-title":"J Clin Oncol"},{"key":"2026070905433222900_bib58","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1530\/ERC-11-0367","article-title":"Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study","volume":"19","author":"Kvols","year":"2012","journal-title":"Endocr Relat Cancer"},{"key":"2026070905433222900_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102560","article-title":"Targeting neuroendocrine tumors with octreotide and lanreotide: key points for clinical practice from NET specialists","volume":"117","author":"La Salvia","year":"2023","journal-title":"Cancer Treat Rev"},{"key":"2026070905433222900_bib60","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1080\/17474124.2018.1489232","article-title":"Somatostatin analogue-induced pancreatic exocrine insufficiency in patients with neuroendocrine tumors: results of a prospective observational study","volume":"12","author":"Lamarca","year":"2018","journal-title":"Expet Rev Gastroenterol Hepatol"},{"key":"2026070905433222900_bib61","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2022.03.027","article-title":"Health-related quality of life in patients with advanced well-differentiated pancreatic and extrapancreatic neuroendocrine tumors treated with surufatinib versus placebo: results from two randomized, double-blind, phase III trials (SANET-p and SANET-ep)","volume":"169","author":"Li","year":"2022","journal-title":"Eur J Cancer"},{"key":"2026070905433222900_bib62","article-title":"A randomized phase II trial of captem or folfiri as second-line therapy in neuroendocrine carcinomas","volume":"208","author":"Liverani","year":"2024","journal-title":"Eur J Cancer"},{"key":"2026070905433222900_bib63","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1093\/annonc\/mdq721","article-title":"Choosing between the EORTC QLQ-C30 and FACT-G for measuring health-related quality of life in cancer clinical research: issues, evidence and recommendations","volume":"22","author":"Luckett","year":"2011","journal-title":"Ann Oncol"},{"key":"2026070905433222900_bib64","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3390\/cancers15010115","article-title":"The effects of radioligand therapy on quality of life and sexual function in patients with neuroendocrine neoplasms","volume":"15","author":"Malandrino","year":"2023","journal-title":"Cancers"},{"key":"2026070905433222900_bib65","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1053\/j.semnuclmed.2024.05.001","article-title":"Radioligand therapy in patients with lung neuroendocrine tumors: a systematic review on efficacy and safety","volume":"54","author":"Malandrino","year":"2024","journal-title":"Semin Nucl Med"},{"key":"2026070905433222900_bib66","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s00259-017-3816-z","article-title":"Improving quality of life in patients with pancreatic neuroendocrine tumor following peptide receptor radionuclide therapy assessed by EORTC QLQ-C30","volume":"45","author":"Marinova","year":"2018","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"2026070905433222900_bib67","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1007\/s00259-019-04431-3","article-title":"Quality of life in patients with midgut NET following peptide receptor radionuclide therapy","volume":"46","author":"Marinova","year":"2019","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"2026070905433222900_bib68","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.2967\/jnumed.117.204834","article-title":"Quality of life in patients with metastatic gastroenteropancreatic neuroendocrine tumors receiving peptide receptor radionuclide therapy: information from a monitoring program in clinical routine","volume":"59","author":"Martini","year":"2018","journal-title":"J Nucl Med"},{"key":"2026070905433222900_bib69","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2407-13-427","article-title":"Antiproliferative effects of lanreotide autogel in patients with progressive, well-differentiated neuroendocrine tumours: a Spanish, multicentre, open-label, single arm phase II study","volume":"13","author":"Mart\u00edn-Richard","year":"2013","journal-title":"BMC Cancer"},{"key":"2026070905433222900_bib70","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1159\/000456619","article-title":"Impact of vitamin D on the clinical outcome of gastro-entero-pancreatic neuroendocrine neoplasms: report on a series from a single institute","volume":"105","author":"Massironi","year":"2017","journal-title":"Neuroendocrinology"},{"key":"2026070905433222900_bib71","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-020-07581-y","article-title":"Recent epidemiology of patients with gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NEN) in Japan: a population-based study","volume":"20","author":"Masui","year":"2020","journal-title":"BMC Cancer"},{"key":"2026070905433222900_bib72","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.ejca.2013.12.011","article-title":"Capecitabine and streptozocin \u00b1 cisplatin in advanced gastroenteropancreatic neuroendocrine tumours","volume":"50","author":"Meyer","year":"2014","journal-title":"Eur J Cancer"},{"key":"2026070905433222900_bib73","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1016\/j.ejca.2014.10.001","article-title":"Bevacizumab plus capecitabine in patients with progressive advanced well-differentiated neuroendocrine tumors of the gastro-intestinal (GI-NETs) tract (BETTER trial) \u2013 a phase II non-randomised trial","volume":"50","author":"Mitry","year":"2014","journal-title":"Eur J Cancer"},{"key":"2026070905433222900_bib74","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1080\/17446651.2022.2099840","article-title":"Therapeutic strategies for patients with neuroendocrine neoplasms: current perspectives","volume":"17","author":"Modica","year":"2022","journal-title":"Expet Rev Endocrinol Metabol"},{"key":"2026070905433222900_bib75","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1007\/s40618-022-01872-w","article-title":"Health-related quality of life in patients with neuroendocrine neoplasms: a two-wave longitudinal study","volume":"45","author":"Modica","year":"2022","journal-title":"J Endocrinol Investig"},{"key":"2026070905433222900_bib76","doi-asserted-by":"crossref","first-page":"8957","DOI":"10.3390\/ijms25168957","article-title":"Role of bone metastases in lung neuroendocrine neoplasms: clinical presentation, treatment and impact on prognosis","volume":"25","author":"Modica","year":"2024","journal-title":"Int J Mol Sci"},{"key":"2026070905433222900_bib77","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJM198011203032101","article-title":"Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma","volume":"303","author":"Moertel","year":"1980","journal-title":"N Engl J Med"},{"key":"2026070905433222900_bib78","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1056\/NEJM199202203260804","article-title":"Streptozocin\u2013doxorubicin, streptozocin\u2013fluorouracil, or chlorozotocin in the treatment of advanced islet-cell carcinoma","volume":"326","author":"Moertel","year":"1992","journal-title":"N Engl J Med"},{"key":"2026070905433222900_bib79","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1634\/theoncologist.2017-0255","article-title":"Sarcopenia is associated with quality of life and depression in patients with advanced cancer","volume":"23","author":"Nipp","year":"2018","journal-title":"Oncologist"},{"key":"2026070905433222900_bib80","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/(SICI)1097-0142(20000215)88:4<770::AID-CNCR6>3.0.CO;2-0","article-title":"Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance","volume":"88","author":"O\u2019Toole","year":"2000","journal-title":"Cancer"},{"key":"2026070905433222900_bib81","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s40618-024-02448-6","article-title":"Radioligand therapy in the therapeutic strategy for patients with gastro-entero-pancreatic neuroendocrine tumors: a consensus statement from the Italian Association for Neuroendocrine Tumors (Itanet), Italian Association of Nuclear Medicine (AIMN), Italian Society of Endocrinology (SIE), Italian Association of Medical Oncology (AIOM)","volume":"48","author":"Panzuto","year":"2024","journal-title":"J Endocrinol Investig"},{"key":"2026070905433222900_bib82","first-page":"1","article-title":"Epidemiology of gastroenteropancreatic neuroendocrine neoplasms: a review and protocol presentation for bridging tumor registry data with the Italian association for neuroendocrine tumors (Itanet) national database","author":"Panzuto","year":"2024","journal-title":"Endocrine"},{"key":"2026070905433222900_bib83","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s11523-016-0440-y","article-title":"Safety and QOL in patients with advanced NET in a phase 3b expanded access study of everolimus","volume":"11","author":"Pavel","year":"2016","journal-title":"Targeted Oncol"},{"key":"2026070905433222900_bib84","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1016\/S1470-2045(17)30471-0","article-title":"Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"18","author":"Pavel","year":"2017","journal-title":"Lancet Oncol"},{"key":"2026070905433222900_bib85","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1530\/ERC-17-0455","article-title":"Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial","volume":"25","author":"Pavel","year":"2018","journal-title":"Endocr Relat Cancer"},{"key":"2026070905433222900_bib86","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.annonc.2020.03.304","article-title":"Gastroenteropancreatic neuroendocrine neoplasms: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Pavel","year":"2020","journal-title":"Ann Oncol"},{"key":"2026070905433222900_bib87","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.ejca.2021.06.056","article-title":"Efficacy and safety of high-dose lanreotide autogel in patients with progressive pancreatic or midgut neuroendocrine tumours: CLARINET FORTE phase 2 study results","volume":"157","author":"Pavel","year":"2021","journal-title":"Eur J Cancer"},{"key":"2026070905433222900_bib88","first-page":"3695","article-title":"Health-related quality of life in patients with neuroendocrine tumors: an investigation of treatment type, disease status, and symptom burden","volume":"24","author":"Pearman","year":"2016","journal-title":"Support Care Cancer"},{"key":"2026070905433222900_bib89","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.21037\/jgo-22-874","article-title":"Outcome analysis in patients with metastatic gastroenteropancreatic neuroendocrine tumors receiving peptide receptor radionuclide therapy with Lu-177-DOTATATE","volume":"14","author":"Pr\u00e9tot","year":"2023","journal-title":"J Gastrointest Oncol"},{"key":"2026070905433222900_bib90","doi-asserted-by":"crossref","first-page":"e010765","DOI":"10.1136\/bmjopen-2015-010765","article-title":"Screening for malnutrition in patients with gastro-entero-pancreatic neuroendocrine tumours: a cross-sectional study","volume":"6","author":"Qureshi","year":"2016","journal-title":"BMJ Open"},{"key":"2026070905433222900_bib91","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1159\/000497330","article-title":"Observational study to assess quality of life in patients with pancreatic neuroendocrine tumors receiving treatment with everolimus: the OBLIQUE study (UK phase IV trial)","volume":"108","author":"Ramage","year":"2019","journal-title":"Neuroendocrinology"},{"key":"2026070905433222900_bib92","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1056\/NEJMoa1003825","article-title":"Sunitinib malate for the treatment of pancreatic neuroendocrine tumors","volume":"364","author":"Raymond","year":"2011","journal-title":"N Engl J Med"},{"key":"2026070905433222900_bib93","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1159\/000491999","article-title":"Efficacy and safety of sunitinib in patients with well-differentiated pancreatic neuroendocrine tumours","volume":"107","author":"Raymond","year":"2018","journal-title":"Neuroendocrinology"},{"key":"2026070905433222900_bib94","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1023\/A:1008996223999","article-title":"Recommendations on health-related quality of life research to support labeling and promotional claims in the United States","volume":"9","author":"Revicki","year":"2000","journal-title":"Qual Life Res"},{"key":"2026070905433222900_bib95","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","article-title":"Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group","volume":"27","author":"Rinke","year":"2009","journal-title":"J Clin Oncol"},{"key":"2026070905433222900_bib96","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1159\/000443612","article-title":"Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors (PROMID): results of long-term survival","volume":"104","author":"Rinke","year":"2017","journal-title":"Neuroendocrinology"},{"key":"2026070905433222900_bib97","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1159\/000499469","article-title":"Health-related quality of life for long-acting octreotide versus placebo in patients with metastatic midgut neuroendocrine tumors in the phase 3 PROMID trial","volume":"109","author":"Rinke","year":"2019","journal-title":"Neuroendocrinology"},{"key":"2026070905433222900_bib98","doi-asserted-by":"crossref","first-page":"6777","DOI":"10.1245\/s10434-023-13729-4","article-title":"Surgery improves patient-reported outcomes in patients with intestinal and pancreatic NETs: a prospective analysis","volume":"30","author":"Rosowicz","year":"2023","journal-title":"Ann Surg Oncol"},{"key":"2026070905433222900_bib99","article-title":"Quality of Life (Qol) with lanreotide autogel (Lan) vs. placebo in patients with enteropancreatic neuroendocrine tumours (Ep-Nets): results from the Clarinet phase III study","volume":"25","author":"Ruszniewski","year":"2014","journal-title":"Ann Oncol"},{"key":"2026070905433222900_bib100","doi-asserted-by":"crossref","first-page":"e316","DOI":"10.1210\/clinem\/dgaa760","article-title":"Quality of life in patients with neuroendocrine neoplasms: the role of severity, clinical heterogeneity, and resilience","volume":"106","author":"Scandurra","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070905433222900_bib101","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1016\/S0140-6736(24)00701-3","article-title":"[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high-dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2\u20133, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study","volume":"403","author":"Singh","year":"2024","journal-title":"Lancet"},{"key":"2026070905433222900_bib102","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of 177 Lu-Dotatate for midgut neuroendocrine tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N Engl J Med"},{"key":"2026070905433222900_bib103","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1200\/JCO.2018.78.5865","article-title":"Health-related quality of life in patients with progressive midgut neuroendocrine tumors treated with 177Lu-Dotatate in the phase III NETTER-1 trial","volume":"36","author":"Strosberg","year":"2018","journal-title":"J Clin Oncol"},{"key":"2026070905433222900_bib104","doi-asserted-by":"crossref","DOI":"10.1186\/s12874-016-0289-x","article-title":"Measuring health-related quality of life in cervical cancer patients: a systematic review of the most used questionnaires and their validity","volume":"17","author":"Tax","year":"2017","journal-title":"BMC Med Res Methodol"},{"key":"2026070905433222900_bib105","doi-asserted-by":"crossref","first-page":"2724","DOI":"10.1200\/JCO.2004.10.016","article-title":"Quality of life in patients with gastroenteropancreatic tumors treated with [177Lu-DOTA0,Tyr3]octreotate","volume":"22","author":"Teunissen","year":"2004","journal-title":"J Clin Oncol"},{"key":"2026070905433222900_bib106","doi-asserted-by":"crossref","first-page":"17","DOI":"10.4103\/2347-5625.152402","article-title":"Factors affecting the quality of life of cancer patients undergoing chemotherapy: a questionnaire study","volume":"2","author":"\u00dcst\u00fcndag","year":"2015","journal-title":"Asia Pac J Oncol Nurs"},{"key":"2026070905433222900_bib107","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1097\/MPA.0b013e31819b6441","article-title":"Development of the Norfolk quality of life tool for assessing patients with neuroendocrine tumors","volume":"38","author":"Vinik","year":"2009","journal-title":"Pancreas"},{"key":"2026070905433222900_bib108","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s11523-016-0462-5","article-title":"Patient-reported outcomes and quality of life with sunitinib versus placebo for pancreatic neuroendocrine tumors: results from an international phase III trial","volume":"11","author":"Vinik","year":"2016","journal-title":"Targeted Oncol"},{"key":"2026070905433222900_bib109","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.4158\/EP151172.OR","article-title":"Evaluation of lanreotide depot\/autogel efficacy and safety as A carcinoid syndrome treatment (elect): a randomized, double-blind, placebo-controlled trial","volume":"22","author":"Vinik","year":"2016","journal-title":"Endocr Pract"},{"key":"2026070905433222900_bib110","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s11154-024-09937-2","article-title":"Nutritional status and gastroenteropancreatic neuroendocrine neoplasms: lights and shadows with a clinical guide from the NIKE group","volume":"26","author":"Vitale","year":"2024","journal-title":"Rev Endocr Metab Disord"},{"key":"2026070905433222900_bib111","article-title":"Incidence and survival of neuroendocrine neoplasia in England 1995\u20132018: a retrospective, population-based study","volume":"23","author":"White","year":"2022","journal-title":"Lancet Reg Health Eur"},{"key":"2026070905433222900_bib112","doi-asserted-by":"crossref","first-page":"5075","DOI":"10.2147\/DDDT.S84177","article-title":"Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues","volume":"9","author":"Wolin","year":"2015","journal-title":"Drug Des Dev Ther"},{"key":"2026070905433222900_bib113","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1200\/JCO.1999.17.4.1111","article-title":"Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms","volume":"17","author":"Wymenga","year":"1999","journal-title":"J Clin Oncol"},{"key":"2026070905433222900_bib114","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/S1470-2045(20)30493-9","article-title":"Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Xu","year":"2020","journal-title":"Lancet Oncol"},{"key":"2026070905433222900_bib115","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1016\/S1470-2045(20)30496-4","article-title":"Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Xu","year":"2020","journal-title":"Lancet Oncol"},{"key":"2026070905433222900_bib116","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/bjc.2012.560","article-title":"Validation of the EORTC QLQ-GINET21 questionnaire for assessing quality of life of patients with gastrointestinal neuroendocrine tumours","volume":"108","author":"Yadegarfar","year":"2013","journal-title":"Br J Cancer"},{"key":"2026070905433222900_bib117","doi-asserted-by":"crossref","first-page":"4311","DOI":"10.1200\/JCO.2008.16.7858","article-title":"Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study","volume":"26","author":"Yao","year":"2008","journal-title":"J Clin Oncol"},{"key":"2026070905433222900_bib118","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/S0140-6736(15)00817-X","article-title":"Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study","volume":"387","author":"Yao","year":"2016","journal-title":"Lancet"},{"key":"2026070905433222900_bib119","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1210\/jc.2018-01991","article-title":"Symptomatic and radiological response to 177Lu-DOTATATE for the treatment of functioning pancreatic neuroendocrine tumors","volume":"104","author":"Zandee","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070905433222900_bib120","doi-asserted-by":"crossref","first-page":"e3665","DOI":"10.1210\/clinem\/dgab289","article-title":"Peptide receptor radionuclide therapy with 177Lu-DOTATATE for symptomatic control of refractory carcinoid syndrome","volume":"106","author":"Zandee","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070905433222900_bib121","doi-asserted-by":"crossref","first-page":"717","DOI":"10.3390\/jcm12020717","article-title":"Chemotherapy in well differentiated neuroendocrine tumors (NET) G1, G2, and G3: a narrative review","volume":"12","author":"Zappi","year":"2023","journal-title":"J Clin Med"},{"key":"2026070905433222900_bib122","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1002\/cncr.22554","article-title":"Elevated expression of vascular endothelial growth factor correlates with increased angiogenesis and decreased progression-free survival among patients with low-grade neuroendocrine tumors","volume":"109","author":"Zhang","year":"2007","journal-title":"Cancer"}],"container-title":["Endocrine-Related Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/erc.bioscientifica.com\/view\/journals\/erc\/32\/8\/ERC-24-0303.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/erc.bioscientifica.com\/downloadpdf\/journals\/erc\/32\/8\/ERC-24-0303.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article-pdf\/doi\/10.1530\/ERC-24-0303\/145091\/erc-24-0303.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article-pdf\/doi\/10.1530\/ERC-24-0303\/145091\/erc-24-0303.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T09:43:50Z","timestamp":1783590230000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article\/32\/8\/e240303\/25925\/Impact-of-treatment-on-quality-of-life-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,15]]},"references-count":122,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8,1]]}},"URL":"https:\/\/doi.org\/10.1530\/erc-24-0303","relation":{},"ISSN":["1479-6821","1351-0088"],"issn-type":[{"value":"1479-6821","type":"electronic"},{"value":"1351-0088","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7,15]]},"article-number":"e240303"}}